3Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study [J]. Lancet, 1999, 353 (9156) : 878-882.
4Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures [J]. Lancet, 2002, 359 (9319) : 1761-1767.
5Harris ST, Watts NB, Genant HK, et aL Effects ofrisedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial[J]. JAm Med Asscoi, 1999, 282 (14) : 1344-1352.
6McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women[J]. N Engl J Med, 2001, 344 (5) : 333-340.
7Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [J]. Osteoporos Int, 2000, Ⅱ (1): 83-91.
8Siris ES, Harris ST, Rosen C J, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women relationship to vertebral and nonverterbal fractures from 2 US claims databases [J]. Mayo Clinc Proc, 2006, 81 (8) : 1013-1022.
9Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice[J]. Osteoporos Int, 2004, 15 (12) : 1003-1008.
10McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis[J]. Maturitas, 2004, 48 (3):271-287.
